HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

nidogen (entactin)

basal lamina-associated sulfated glycoprotein; GenBank AJ224450 (rat); RefSeq NM_010917 (mouse); NM_002508 (human)

Also Known As:

entactin; NID1 protein, human; Nid protein, rat; Nid1 protein, mouse; Nid1 protein, rat; enactin protein, human; entactin protein, rat; entactin-1 protein, mouse; nidogen 1; nidogen 1 protein, human; nidogen 1 protein, mouse; nidogen protein, rat; nidogen-1

Networked: 112 relevant articles (0 outcomes, 5 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 58375
  - Glycoproteins: 14359
    - Membrane Glycoproteins: 1506
      - nidogen: 112
  - Membrane Proteins: 4076
    - Membrane Glycoproteins: 1506
      - nidogen: 112

Experts

1.	Seo, In Ae: 3 articles (08/2009 - 04/2006)
2.	Park, Hwan Tae: 3 articles (08/2009 - 04/2006)
3.	Lee, Hyun Kyoung: 3 articles (08/2009 - 04/2006)
4.	Smyth, Neil: 2 articles (01/2010 - 12/2006)
5.	Nischt, Roswitha: 2 articles (01/2010 - 12/2006)
6.	Miosge, Nicolai: 2 articles (01/2010 - 05/2008)
7.	Park, Hye Kyung: 2 articles (08/2007 - 04/2006)
8.	Zheng, Yingye: 1 article (03/2010)
9.	Soosaipillai, Antoninus: 1 article (03/2010)
10.	Li, Lin: 1 article (03/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2007 - "Immuno-staining for nidogen-2 confirmed the correlation between aberrant methylation and loss of nidogen expression also in primary tumors, implying that aberrant methylation was a mechanism for inhibiting nidogens expression in human gastrointestinal tumors. " 04/17/2006 - "Identification of the basement membrane protein nidogen as a candidate ligand for tumor endothelial marker 7 in vitro and in vivo." 06/01/1995 - "Nidogen was confined to basement membranes of tumor blood vessels. " 10/01/1991 - "Apparent molecular weight, amino acid composition, and molecular configuration by electron microscopy rotary shadowing were similar to that of nidogen from EHS mouse tumor. " 06/25/1990 - "Furthermore, the peptide RGDS could inhibit the attachment of mouse mammary tumor cells to entactin to approximately 60% of control. " Order ALL the reference details at left...
2.	Carcinoma (Carcinomatosis) 03/01/1999 - "The results show that nidogen is produced by human carcinoma cells both in vitro and in vivo." 03/01/1999 - "There was strong immunoreactivity for nidogen in tumour stroma, BM of carcinoma cell nests, and endothelial basal lamina, but no conclusions could be drawn regarding histological grade and immunostaining patterns, because stromal production could not be ruled out. " 09/15/1992 - "We report here the isolation and identification of the plasma membrane receptor for entactin from PC-3 human prostate carcinoma cells which attach and spread on entactin. " 09/15/1992 - "These data demonstrate that the cell surface receptor for entactin on these prostate carcinoma cells is the integrin alpha 3 beta 1 and that these cells utilize alpha 6 beta 1 as the receptor for laminin." 07/01/1984 - "Induction of rat yolk sac carcinomas with consistent pattern of laminin, entactin, and type IV collagen biosynthesis." Order ALL the reference details at left...
3.	Experimental Sarcoma 02/15/1988 - "Immunofluorescent studies, using the monoclonal antibody on sections of the EHS tumor after proteolytic digestion, showed that the retention or disappearance of the Nd-40 determinant correlated with the in vitro digestion pattern of the laminin-nidogen complex." 09/01/1992 - "Nidogen, obtained from the EHS tumor or in recombinant form, binds exclusively to the protein core in a heparin-insensitive manner. " 09/01/1992 - "A large, low-density form of heparan sulfate proteoglycan was isolated from the Engelbreth-Holm-Swarm (EHS) tumor and demonstrated to bind in immobilized-ligand assays to laminin fragment E3, collagen type IV, fibronectin and nidogen. " 08/01/1986 - "Further, the EBA antigen is absent from serum and blood components, placenta, amnion, lung, and the EHS tumor, a murine sarcoma that produces large amounts of laminin, type IV collagen, nidogen, entactin, and basement membrane proteoglycan but is present in cutaneous tumors of adnexal and epithelial origin. " Order ALL the reference details at left...
4.	Nephritis 10/01/1994 - "CONCLUSION--The study demonstrates that anti-entactin antibodies are present in a significant number of patients with SLE and tend to be more common in those with severe disease, with or without nephritis, than in patients with mild disease manifestations. " 08/01/1990 - "Entactin: a possible auto-antigen in the pathogenesis of non-Goodpasture anti-GBM nephritis." Order ALL the reference details at left...
5.	Reperfusion Injury 06/01/1998 - "Western blots showed a marked increase in the urinary 55 kDa nidogen fragment as early as the first day following ischemia-reperfusion injury and continuing for six days. " 06/01/1998 - "Since in our in vitro studies, we identified a distinct meprin-induced 55 kDa nidogen breakdown product, the urine was also examined for the presence of nidogen degradation products after rat renal ischemia-reperfusion injury. " 06/01/1998 - "Taken together, these in vivo data strongly support the notion that the nidogen breakdown products are the result of partial degradation of tubular basement membrane by meprin A following renal tubular ischemia-reperfusion injury." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Laminin (Merosin)
2.	Collagen Type IV (Type IV Collagen)
3.	Collagen
4.	Antibodies
5.	heparin proteoglycan
6.	Thiopronine (Tiopronin)
7.	Fibronectins (Fibronectin)
8.	nidogen (entactin)
9.	Proteins (Proteins, Gene)
10.	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)

Related Therapies and Procedures

1.	Axotomy
2.	Nephrectomy

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20728 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>